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The management of respiratory tract infections has been complicated 
in recent years by the emergence of antimicrobial resistance, parti- 
cularly in tile pneumococcus. While clinical cure remains the 
primary criterion for antibiotic choice, increasing attention is being 
given to the selective pressure exerted by antibiotics on the major 
respiratory pathogens. A iiuniber of recent studies have focused on 
the impact of antibiotics on the selection of resistant pneumococci 111 
the nasopharynx. There is evidence that less active oral cephalo- 
sporins select for the carriage and, therefore, the probable 
dissemination of resistant strains to a greater extent than more active 
oral p-lactams. Certain classes of antimicrobial may select for 
multiply-resistant strains, Penicillin-resistant pneumococci may 
therefore be selected by the use of macrolides, tri- 
iiiethopriiii-sulfaiiiethoxazole or 1%-lactains. Reduction in the use of 
triiiiethopriiii-\ulfaniethoxazole and/or nracrolides may therefore 
reduce penicillin resistance in pneuinococci. Fluoroquinolone resist- 
ance has recently emerged in some of the major niultiresistant 
pneumococcal clones which have disseminated worldwide. More 
data are needed on the ecological impact of fluoroquinolone use on  
pneuniococcal recistance. Various approaches have been used to 
reduce the incidence of multiresistant pneuniococci. These include 
classic approaches to infection control, treatment of carriers and 
conjugate pneumococcal vaccination. It is possible that the intro- 
duction of conjugate pneuniococcal vaccine may greatly reduce the 
burden of antimicrobial resistance among respiratory pathogens in 
children. 
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Community-acquired pneumonia (CAP) has a major impact upon 
the individud patient and upon society as a whole. In the USA alone 
there are three to four million cases yearly with approximately 
600 000 hospitalizations. The disease accounts for approximately 64 
million days of restricted activity and 78 000 deaths annually. The 
cost of care is estimated at approximately 1/4 billion dollars per year. 
Dcspite nrr itrcrease i t i  our irndcrsfariding i$ the etiolo'qy and the 
patliogeriesis of CAT: m u  diacqriostir niethods are still relatively rudinietrfary 
arid pliysiriarrs rnu.r/ ~ f " n  rtsorf ro rmpirical fherapyJor initial treatmenr. 
We now recognize that CAP is not a single uniform entity and 
that the etiologic agents niay vary depending upon the age and co- 
morbid conditions of  the patient. where the infection was acquired 
and the severity of illness. The pneumococcus continues to be a 
significant pathogen but it is becoming clear that the atypical 
respiratory agents such as Myroplasma pneurnotiiac and Clilanrydia 
pneutnorriae are important as well. Increasing antimicrobial resistance 
is a problem worldwide but the clinical relevance is not always 
ininiediately apparent. 
Treatment decisions are influenced by the large number of 
potential etiologic agents, the possibility of co-infection with more 
than one pathogen, resistance and often inadequate diagnostic 
methods. The site of care decision is also an important determinant 
of treatment. 
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The  incidence of bacterial pneunioiii~ is higher in HIV-infected 
persons, especially, in intravenous drug addicts, than in the non- 
infected. It is encountered at a higher rate as the numbers of CI)4 
cells decrease. It is an AIDS-defining went if it is recurrent within 
12 months. Ptieurnoryystis carinii as a cause of pneumonia is still very 
frequent despite the widespread introduction of primary and 
secondary prophylaxis. Other important pathogens reported from 
different centers in Europe include Cryptococcns and A s p q i / / i i s ,  
depending on  the local epidemiology. Recurrent bacterial piieu- 
monia as the first manifestation ofAIDS is very rare in patients at o u r  
center. Bacterial pneumonia as the first manifestation was diagnosed 
in only 1 0  of 1708 patients seen in 1984-95. However, they 
comprised up to 10% of all AIDS-defining manifestations. With the 
introduction of highly active antiretroviral treatment, the rate of 
coniiiiunity-acquired bacterial pneumonia per year has dropped from 
56/402 (nuniber of events/number of p<itientr) in  1992 t o  16/51 1 in 
1996. I'reliminary analysis of the most recent years confirms this 
trend. A siniilar drop l iar  bccn observed in the rate of Prrc~irrirorpis 
caririii infection. Sfre~~tocorrus ptrcumorriae (50'%), Haf~ni t~pki / i fs  i t ~ f l u c r i a c  
(24%), Psendonronas aen{qiriosa (16%) and SIap/iykicorciss nrtr('irs (7%) are 
still the most fiequent bacterial pathogens. 
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Second-generation fluoroquinolones have proved to he of great value 
in acute exacerbations of chronic bronchitis (AECU) caused by 
Hacwiophilus i~f luet izae and Moraxella mtarrlralis, and in CAP cauced 
by these pathogens, atypical organisms and Lqiorielh spp, Howevcr, 
the activity of ciprofloxacin and ofloxacin (MICCJII range5 0.5- 
4 nig/L) against Sfrcptoroccns pvreirnroniat. was reflected by le\s than 
optimal clinical results in severe pneumococcal infectioiic. Levo- 
floxacin (the L-isomer of ofloxacin) has moderately improved activity 
(MICCN 1 mg/L) and clinical activity. Third-generation fluoro- 
quinolones have now been developed with significantly increased 
activity against both penicillin-sensitive and niultidrug-resistant S. 
pimrtnorriae (DRSP), ranging from sparfloxacin (MICVII 0.5 mg/L) 
and grepafloxacin (MICYI, 0.25 nig/L) to  the 7-azabtcyclo coni- 
pounds trovafloxacin and moxifloxacin (MICW 0.1 2 ing/L). 
Pharniacodynamic studies, using C,,,,,/MIC, AUIC and epithelial 
fluid/MIC ratios, predict significantly improved results in pneunio- 
coccal infections which are confirmed by clinical trials. In both 
domiciliary and hospitalized patients, third-generation agents give 
clinical success rates of 85-95%, equaling or exceeding standard 
comparators, for both penicillin-sensitive and DRSP infection\, and 
in those caused by Mycop/asma ptieumoniae and Chlanrydia pneumotriac. 
These agents, partly differentiable by adverse reaction profiles, offer 
effective therapeutic alternatlves in the face of increasingly prevalent 
pneuniococcal resistance to beta-lactams and macro-azalides. 
